Anne-Marie Leuck, MD
Infectious Disease · Minneapolis, MNNPI 1275728677
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $35 of the $51 with a category attached, or 68.0%. Shionogi Inc accounts for 68.0% of it on its own, with 1 other manufacturer making up the rest.
Across 2 payments — averaging $25.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$35
- Insmed, Inc.$16
Across 30 payments — averaging $8596.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$258K
What the payments were for
- Food & beverage$3568%
- Education$1632%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 1 | $35 |
| Insmed, Inc. | 1 | $16 |
How this compares
$51 in reported general payments places this provider in the 60th percentile of 157 infectious disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 49 | $191,632 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $51,841 |
| Daptomycin | 38 | $31,242 |
| Darunavir | 19 | $23,870 |
| Etravirine | 12 | $14,691 |
| Cefadroxil | 46 | $2,810 |
| Cefpodoxime Proxetil | 17 | $1,759 |
| Doxycycline Hyclate | 34 | $926 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 20 | $470 |
| Ciprofloxacin Hcl | 16 | $288 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 31 | $285 |
| Allopurinol | 13 | $63 |
| Omeprazole | 17 | $38 |
| Mupirocin | 13 | $1 |
| Zolpidem Tartrate | 13 | $1 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Minneapolis
- Frank RhameMinneapolis$132K
- William HenryMinneapolis$7K
- William StaufferMinneapolis$5K
- Grishma TrivediMinneapolis$3K
- Alison BormannMinneapolis$3K
- Karam ObeidMinneapolis$3K
- Jo Anne YoungMinneapolis$2K
- David BoulwareMinneapolis$2K
- Michele GranadaMinneapolis$430
- Christian SchrockMinneapolis$230
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.